Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective vigilantly but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the last several shares of mine. My first CytoDyn article, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire interview that I came away with a bad viewpoint of the company.

Irony of irony, the bad viewpoint of mine of the company has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of this technology and associated intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) plus the first brand new drug application endorsement ($five million), as well as royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it’s this single remedy and a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

Its opening banner on the site of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications in addition to multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself through the really start of the interest of mine in this business. Judging with the multiples of a huge number of various responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a classic battleground, or perhaps some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *